RE:AlsoDuster340 wrote: i noticed that there was no insider buying, when the stock was in the 40 cent range.
I know there are plans for insiders to buy more shares. Unfortunately, the details of when and how many shares ... will remain a mystery.
John's purpose for selling is complex and personal. Don't know if he's done and don't know if he'll require more cash. Just an unfortunate set of personal events. I will also take a stab at it ... to say it all likely also relates to him vacating the CSO position (at least in my head). Do I know that for sure - no - but this is how it all starts to make sense to me.
Regardless ... I look at 2023 mostly related to P2-acute and the chronic work to come out of the PK studies.
I also look to the IBD announcement and how our drug has the potential to make its mark in a different and unique way where IBD and IBS are concerned. If we can make headway in pill form here - we further upsize our funnel potential. Just what we want going into P2-acute/readout.
So much on the go as we make our way to potential negotiations.